Morningstar Investment Management LLC Makes New $1.03 Million Investment in Thermo Fisher Scientific Inc. $TMO

Morningstar Investment Management LLC bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, HoldingsChannel reports. The firm bought 2,540 shares of the medical research company’s stock, valued at approximately $1,030,000.

A number of other institutional investors have also modified their holdings of TMO. Brighton Jones LLC raised its stake in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the period. GAMMA Investing LLC raised its stake in Thermo Fisher Scientific by 22.0% during the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock worth $2,419,000 after acquiring an additional 877 shares during the period. Elevation Point Wealth Partners LLC raised its stake in Thermo Fisher Scientific by 12.2% during the first quarter. Elevation Point Wealth Partners LLC now owns 1,366 shares of the medical research company’s stock worth $680,000 after acquiring an additional 149 shares during the period. Finally, Dynamic Advisor Solutions LLC acquired a new stake in Thermo Fisher Scientific during the first quarter worth about $2,218,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on TMO. Raymond James Financial reiterated an “outperform” rating and set a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. UBS Group upped their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday. Weiss Ratings restated a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Finally, William Blair assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating for the company. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $589.10.

Insider Activity

In other news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 over the last three months. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $524.80 on Tuesday. The firm has a 50 day simple moving average of $489.83 and a 200-day simple moving average of $447.66. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The stock has a market capitalization of $198.17 billion, a PE ratio of 30.35, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business’s revenue was up 2.9% on a year-over-year basis. During the same period last year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.